Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences, Inc. (NASDAQ:CSTL), filed a Form 4 on November 4, 2026, disclosing sales of common stock executed on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences, a molecular diagnostics company listed on NASDAQ.
  • Transaction date: All sales were executed on November 2, 2026, pursuant to a Rule 10b5-1 plan adopted June 2, 2026.
  • Direct sales, tranche one: 7,555 shares sold at a weighted-average price of $36.005, with individual trade prices ranging from $35.610 to $36.593.
  • Direct sales, tranche two: 1,025 shares sold at a weighted-average price of $36.814, with individual trade prices ranging from $36.610 to $37.030.
  • Indirect sales: Shares were also sold from The Maetzold Descendants 2020 Trust and Derek Maetzold 2020 Irrevocable Trust on the same date and at the same weighted-average prices.
  • Post-transaction direct holdings: Following the reported transactions, Maetzold directly held 4,929 shares after the first tranche and 3,904 shares after the second tranche, according to the filing.
  • Multiple indirect holdings remain: The filing lists several trusts, including DJM Grantor Retained Annuity Trust No. 8, which holds 40,935 shares indirectly.

Maetzold's November 2026 Sales and Remaining Trust Holdings at Castle Biosciences

According to the filing, Derek J. Maetzold, who serves as President and Chief Executive Officer and is also a director of Castle Biosciences, Inc., disposed of shares of common stock across six separate transactions on November 2, 2026. The filing identifies Castle Biosciences as trading on NASDAQ under the symbol CSTL. All sales were made pursuant to a Rule 10b5-1 plan that Maetzold adopted on June 2, 2026, which the filing notes is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

The directly held shares sold included 7,555 shares at a weighted-average price of $36.005, with trades ranging from $35.610 to $36.593, and 1,025 shares at a weighted-average price of $36.814, with trades ranging from $36.610 to $37.030. Additional shares were disposed of indirectly through two trusts: The Maetzold Descendants 2020 Trust, of which Maetzold's spouse is trustee and whose beneficiaries include the spouse and children, and the Derek Maetzold 2020 Irrevocable Trust, of which Maetzold is the trustee and whose beneficiaries are his children. The filing states that Maetzold undertakes to provide full details of individual trade prices upon request to the SEC, the issuer, or any security holder.

Beyond the sold positions, the filing reports a range of indirect holdings remaining in various trusts. These include four Maetzold 2018 Remainder Trusts, each holding 11,256 shares for the benefit of individual children, and four DJM Grantor Retained Annuity Trusts holding 11,963, 27,862, 40,935, and 23,216 shares, respectively. Maetzold is listed as trustee for each of these grantor annuity trusts.

What Was Disclosed

The Form 4 filed on November 4, 2026, discloses that Castle Biosciences CEO Derek J. Maetzold sold common stock directly and through two family trusts on November 2, 2026, under a Rule 10b5-1 plan. Multiple additional trust-held positions were also reported as remaining indirect holdings.